Results 21 to 30 of about 424,390 (258)

Pulmonary hypertension [PDF]

Current Problems in Cardiology, 2004
Pulmonary hypertension, in its simplest sense, is elevation of the pulmonary artery pressure above normal. A multitude of diseases may increase the pulmonary artery pressure and result in right ventricular dysfunction. The treatments of pulmonary hypertension are as varied as its causes.
Vallerie V, McLaughlin, Stuart, Rich
openaire   +2 more sources

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)

Pulmonary Circulation, 2022
Even though pulmonary arterial hypertension (PAH) remains an incurable disease, the combination of PAH‐specific therapies allowed treatment strategies to evolve from symptom‐based ones to others that aim to move patients to low‐risk conditions ...
Abdullah M. Aldalaan, Sarfraz A. Saleemi, Ihab Weheba, Abeer Abdelsayed, Maha M. Aleid, Fatima Alzubi, Hamdeia Zaytoun, Nadeen Alharbi   +7 more
doaj   +1 more source

The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients

BMC Pulmonary Medicine, 2019
Background Pulmonary Hypertension Association UK (PHA-UK) is the only charity in the UK especially for people affected by pulmonary hypertension (PH).
Iain Armstrong, Catherine Billings, David G. Kiely, Janelle Yorke, Carl Harries, Shaun Clayton, Wendy Gin-Sing   +6 more
doaj   +1 more source

Pulmonary hypertension

Nature Reviews Disease Primers
Pulmonary hypertension encompasses a range of conditions directly or indirectly leading to elevated pressures within the pulmonary arteries. Five main groups of pulmonary hypertension are recognized, all defined by a mean pulmonary artery pressure of >20 mmHg: pulmonary arterial hypertension (rare), pulmonary hypertension associated with left-sided ...
Ana Mocumbi, Marc Humbert, Anita Saxena, Zhi-Cheng Jing, Karen Sliwa, Friedrich Thienemann, Stephen L. Archer, Simon Stewart   +7 more
openaire   +3 more sources

Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension

Arthritis Research & Therapy, 2023
Background Patients with systemic sclerosis (SSc) are frequently affected by iron deficiency, particularly those with pulmonary hypertension (PH). The first data indicate the prognostic importance of hypochromic red cells (% HRC) > 2% among patients with
Panagiota Xanthouli, Ojan Gordjani, Nicola Benjamin, Satenik Harutyunova, Benjamin Egenlauf, Alberto M. Marra, Simon Haas, Nicklas Milde, Norbert Blank, Hanns-Martin Lorenz, Christoph Fiehn, Silvia Ulrich, Oliver Distler, Ekkehard Grünig, Christina A. Eichstaedt   +14 more
doaj   +1 more source

Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction This final analysis of a multicenter, prospective postmarketing surveillance study evaluated the safety of daprodustat in patients with chronic kidney disease anemia in routine clinical practice in Japan. Methods Patients who initiated daprodustat between September 2020 and July 2022 were registered.
Tadao Akizawa, Kyomi Kanaya, Kiyomi Aizawa, Masanori Onoki, Hirofumi Ozeki, Kazuko Suzuki, Ai Hayashi, Tomohiko Asamura   +7 more
wiley   +1 more source

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)

Arthritis Research & Therapy, 2019
Objective The objective of this randomized, placebo-controlled, double-blind, parallel group, trial was to assess the effect of ambrisentan on mean pulmonary arterial pressure (mPAP) in patients with systemic sclerosis (SSc) and mildly elevated pulmonary
Zixuan Pan, Alberto M. Marra, Nicola Benjamin, Christina A. Eichstaedt, Norbert Blank, Eduardo Bossone, Antonio Cittadini, Gerry Coghlan, Christopher P. Denton, Oliver Distler, Benjamin Egenlauf, Christine Fischer, Satenik Harutyunova, Panagiota Xanthouli, Hanns-Martin Lorenz, Ekkehard Grünig   +15 more
doaj   +1 more source

Influenza Vaccination Responses in Disabled Stroke Patients: A Single‐Center Prospective Observational Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to investigate the immunological response to influenza vaccination, the incidence and severity of influenza infection, and the side effects of the vaccination in patients with ischemic stroke. Methods This prospective observational study was conducted between 2023 and 2024 at Ramathibodi Hospital.
Achiraya Pakngao, Sureerat Suwatcharangoon, Pintip Ngamjanyapron, Kobporn Boonnak, Thanitta Suangtamai, Porpon Rotjanapan   +5 more
wiley   +1 more source

Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups

Pulmonary Circulation, 2018
Group 3 pulmonary hypertension (PH) is a common complication of advanced chronic lung disease. Our hypothesis was that group 3 PH is associated with a more severe baseline presentation and a more severe prognosis compared to group 1 pulmonary arterial ...
Nader Chebib, Jean-François Mornex, Julie Traclet, François Philit, Chahera Khouatra, Sabrina Zeghmar, Ségolène Turquier, Vincent Cottin   +7 more
doaj   +1 more source

Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective There are limited real‐world data regarding the safety and effectiveness of onasemnogene abeparvovec (OA; Zolgensma) infusion, a one‐time gene replacement therapy, for Japanese patients with spinal muscular atrophy (SMA). We aimed to improve understanding of the real‐world outcomes for OA in Japan.
Kayoko Saito, Kamal Benguerba, Ken Tsuchida, Kazushige Yazawa, Isao Tsumiyama, Hiromitsu Kayama, Sandra P. Reyna, Farid Khan, Richard S. Finkel   +8 more
wiley   +1 more source